It is very clearly. When we talk about life-cycle management, that really does get to the crux of following the drug, both from a safety point of view and also a benefit point of view.
We start monitoring right from the first introduction in human beings, so the first phases of clinical trial we're starting to already plan out how we will construct vigilance. That's the new scheme. The old scheme is a little bit more passive: you wait for something to happen and it gets reported.